Clinical Trial Update: Trifluridine/Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for Refractory Metastatic Colorectal Cancer [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update comparing Trifluridine/Tipiracil plus Regorafenib versus Trifluridine/Tipiracil plus Bevacizumab for refractory metastatic colorec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Colorectal Cancer Recurrent

Drugs mentioned

• Avastin (bevacizumab)
• Lonsurf (trifluridine/tipiracil)
• Stivarga (regorafenib)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Colorectal Cancer Metastatic, Colorectal Cancer Recurrent | Phase 3 | Status: RECRUITING